Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Tecan Group Ltd.. (9/3/18). "Press Release: Tecan Successfully Completes the Acquisition of NuGen Technologies". Männedorf.

Organisations Organisation Tecan Group Ltd. (SIX Swiss Exchange: TECN)
  Group Tecan (Group)
  Organisation 2 NuGen Technologies Inc.
  Group Tecan (Group)
Products Product reagents (bio/biochemical)
  Product 2 genomic technology
Index term Index term NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan
Person Person Brändle, Martin (Tecan 201201 Head Corporate Communications + Investor Relations)
     


The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the acquisition of NuGEN Technologies, Inc. (NuGEN) on August 31, 2018. On August 16, 2018, Tecan announced the acquisition of US-based NuGEN to further expand Tecan's dedicated solutions offering into the new market segment of next-generation sequencing (NGS) reagents and thus further increasing Tecan's overall recurring revenues. NuGEN is a leading provider for innovative NGS kits and genomic sample preparation solutions for the fastest growing field within the genomics area.

From September 1, 2018, NuGEN will be included in the consolidated financial statements of the Tecan Group as a part of the Life Sciences Business segment.

Additional information can be found on the NuGEN webpage:
www.nugen.com


About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2017, Tecan generated sales of CHF 548 million (USD 560 million; EUR 494 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).


For further information:

Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

   
Record changed: 2018-09-04

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Tecan (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px




» top